STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #334 by analyst upside · 2026-08-14
MCRB
Seres Therapeutics, Inc.
Healthcare · Market Cap $45M · P/E 0x
ANALYST PRICE TARGET
+279.5%
implied upside to consensus target
Current Price $4.48
Consensus Target $17.0
Bull Target $22.0
Bear Target $12.0
Analysts Covering 2
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
2
Hold
0
Sell
0
52-Week Low $4.46
52-Week High $29.98
YTD Return -70.4%
FUNDAMENTALS
Market Cap $45M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.29
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $2M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.46
52-Week High $29.98
Current Price $4.48
Bear Target $12.0
Bull Target $22.0
● Now $4.48 ● Target $17.0
TRADING DATA
Avg Volume 87K
YTD Return -70.4%
Analyst Count 2
Consensus Buy
Upside to Target +279.5%
Last Updated 2026-08-14

ANALYST SUMMARY

Seres Therapeutics, Inc. (MCRB) is currently trading at $4.48 with a Wall Street consensus price target of $17.0, implying potential upside of 279.5% over the next 12 months. 2 analysts currently cover MCRB, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $22.0, while the most cautious has a target of $12.0.

MCRB operates in the Healthcare sector with a market capitalisation of $45M. The stock is down 70.4% year-to-date and is currently trading near the lower end of its 52-week range of $4.46 – $29.98.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MCRB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity - Reiterated
Buy → Buy 2026-03-13 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2025-09-24 Building track record
Chardan Capital ↓ Downgrade
Buy → Neutral 2025-05-08 33% win rate (6 calls)
Chardan Capital - Reiterated
Buy → Buy 2025-03-20 33% win rate (6 calls)
Goldman Sachs - Reiterated
Sell → Sell 2025-03-14 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2024-11-14 Building track record
Chardan Capital - Reiterated
Buy → Buy 2024-11-13 33% win rate (6 calls)
JP Morgan ↓ Downgrade
Neutral → Underweight 2024-10-24 43% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
35
out of 100
Coverage depth
8/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →